This is a standard proxy filing. Monitor the company's website or future filings for the full proxy statement (DEF 14A) to see the specific voting items, such as director nominees and executive pay proposals, ahead of the shareholder meeting.
REGN drugs
REGN drug pipeline →- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 12 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 27 $744.35entry
- T+1 · 7mo ago −2.01%α −1.53% · $729.36
- T+5 · 7mo ago −4.72%α −5.12% · $709.19
- T+20 · 6mo ago −14.74%α −19.70% · $634.62
- T+60 · 4mo ago −12.52%α −17.02% · $651.18
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Regeneron Pharmaceuticals has filed definitive additional proxy soliciting materials (DEFA14A) with the SEC. This is a routine filing related to an upcoming shareholder vote, likely covering items such as director elections, executive compensation, or other corporate governance matters. The filing is from the registrant and is definitive, indicating that the final details for the vote have been provided to shareholders. There is no indication of activist involvement or contentious issues.
Key Facts
- Company: Regeneron Pharmaceuticals, Inc. (REGN)
- Form Type: DEFA14A (Definitive Additional Proxy Soliciting Materials)
- Filing Status: Filed by the Registrant, Definitive
- No activist involvement (SC 13D) or dissident campaign indicated
- Filing is routine and administrative in nature
Financial Impact
No direct financial impact from this filing
Risk Factors
- None identified from this specific filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001308179-26-000341 |
| Document: 0001308179-26-000341-index-headers.html | 0001308179-26-000341 |
| Document: 0001308179-26-000341-index.html | 0001308179-26-000341 |
| Document: 0001308179-26-000341.txt | 0001308179-26-000341 |
Track record
53 reports on REGN
11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers